William Holland

646 total citations
33 papers, 537 citations indexed

About

William Holland is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, William Holland has authored 33 papers receiving a total of 537 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Molecular Biology, 18 papers in Oncology and 14 papers in Pulmonary and Respiratory Medicine. Recurrent topics in William Holland's work include Lung Cancer Treatments and Mutations (12 papers), Cancer Genomics and Diagnostics (8 papers) and Colorectal Cancer Treatments and Studies (6 papers). William Holland is often cited by papers focused on Lung Cancer Treatments and Mutations (12 papers), Cancer Genomics and Diagnostics (8 papers) and Colorectal Cancer Treatments and Studies (6 papers). William Holland collaborates with scholars based in United States, United Kingdom and Canada. William Holland's co-authors include Philip C. Mack, David R. Gandara, Primo N. Lara, Angela M. Davies, Paul H. Gumerlock, Rebekah A. Burich, Henry Jay Forman, Hongqiao Zhang, Dashnamoorthy Ravi and Kumuda C. Das and has published in prestigious journals such as Journal of Clinical Oncology, Free Radical Biology and Medicine and Journal of Investigative Dermatology.

In The Last Decade

William Holland

32 papers receiving 524 citations

Peers

Countries citing papers authored by William Holland

Since Specialization

Citations

This map shows the geographic impact of William Holland's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William Holland with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William Holland more than expected).

Fields of papers citing papers by William Holland

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William Holland. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William Holland. The network helps show where William Holland may publish in the future.

Co-authorship network of co-authors of William Holland

This figure shows the co-authorship network connecting the top 25 collaborators of William Holland. A scholar is included among the top collaborators of William Holland based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William Holland. William Holland is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	PTH-3 What is the role of multiple urine GIPs in established coeliac disease? 2021 ·Anupam Rej, William Holland, Graeme Wild, David S. Sanders	0
2	Preclinical Evaluation of MET Inhibitor INC-280 With or Without the Epidermal Growth Factor Receptor Inhibitor Erlotinib in Non–Small-Cell Lung Cancer 2016 ·Clinical Lung Cancer ·(unknown), William Holland, (unknown), Rebekah A. Burich, Primo N. Lara, David R. Gandara, Karen Kelly, Philip C. Mack	34
3	Effects of AKT inhibition on HGF-mediated erlotinib resistance in non-small cell lung cancer cell lines 2014 ·Journal of Cancer Research and Clinical Oncology ·William Holland, (unknown), Primo N. Lara, David R. Gandara, Philip C. Mack	15
4	Anticancer activity of the Aurora A kinase inhibitor MK-5108 in non-small-cell lung cancer (NSCLC) in vitro as monotherapy and in combination with chemotherapies 2014 ·Journal of Cancer Research and Clinical Oncology ·(unknown), William Holland, Philip C. Mack	26
5	Pharmacodynamic separation of gemcitabine and erlotinib in locally advanced or metastatic pancreatic cancer: therapeutic and biomarker results 2014 ·International Journal of Clinical Oncology ·Thomas J. Semrad, Afsaneh Barzi, Heinz‐Josef Lenz, (unknown), Edward Kim, (unknown), Michael Tanaka, Laurel Beckett, William Holland, Rebekah A. Burich, (unknown), Philip C. Mack, Primo N. Lara	24
6	DIVERGENT ACTIVITY OF AFATINIB (AFAT) AND CETUXIMAB (CET) IN PATIENT-DERIVED XENOGRAFT (PDX) MODELS OF ACQUIRED ERLOTINIB RESISTANCE. 2013 ·Journal of Thoracic Oncology ·Philip C. Mack, Neal Goodwin, William Holland, Karen Kelly, Tianhong Li, Primo Lara, David R. Gandara	2
7	Anti‐tumor activity of the HSP90 inhibitor SNX‐2112 in pediatric cancer cell lines 2011 ·Pediatric Blood & Cancer ·(unknown), William Holland, Janet Yoon, Theodore Zwerdling, Philip C. Mack	16
8	Aberrant Regulation of the MRP3 Gene in Non-small Cell Lung Carcinoma 2011 ·Journal of Thoracic Oncology ·(unknown), (unknown), William Holland, Hongqiao Zhang, David R. Gandara, Philip C. Mack, Henry Jay Forman	14
9	Evaluating rational non-cross-resistant combination therapy in advanced clear cell renal cell carcinoma: combined mTOR and AKT inhibitor therapy 2011 ·Cancer Chemotherapy and Pharmacology ·William Holland, Clifford G. Tepper, Jose E. Pietri, (unknown), David R. Gandara, Philip C. Mack, Primo N. Lara	17
10	EGFR Mutations Detected in Plasma Are Associated with Patient Outcomes in Erlotinib Plus Docetaxel-Treated Non-small Cell Lung Cancer 2009 ·Journal of Thoracic Oncology ·Philip C. Mack, William Holland, Rebekah A. Burich, Randeep Sangha, (unknown), Yueju Li, Laurel Beckett, Primo N. Lara, Angela M. Davies, David R. Gandara	61
11	Multidrug-resistant protein-3 gene regulation by the transcription factor Nrf2 in human bronchial epithelial and non-small-cell lung carcinoma 2009 ·Free Radical Biology and Medicine ·(unknown), Hongqiao Zhang, Alessandra Rinna, William Holland, Philip C. Mack, Henry Jay Forman	56
12	KRAS mutation analysis in cetuximab-treated advanced stage non-small cell lung cancer (NSCLC): SWOG experience with S0342 and S0536 2009 ·Journal of Clinical Oncology ·Philip C. Mack, William Holland, Mary W. Redman, Primo N. Lara, (unknown), Fred R. Hirsch, Wilbur A. Franklin, (unknown), Roy S. Herbst, David R. Gandara	21
13	Predictive value of EGFR and KRAS mutations detected in plasma from non-small cell lung cancer (NSCLC) patients treated with docetaxel and intermittent erlotinib 2008 ·Journal of Clinical Oncology ·Philip C. Mack, William Holland, Rebekah A. Burich, (unknown), Laurel Beckett, Primo N. Lara, Angela M. Davies, David R. Gandara	1
14	Genistein combined polysaccharide enhances activity of docetaxel, bicalutamide and Src kinase inhibition in androgen‐dependent and independent prostate cancer cell lines 2008 ·British Journal of Urology ·Rebekah A. Burich, William Holland, Ruth L. Vinall, Clifford G. Tepper, Ralph W. deVere White, Philip C. Mack	19
15	Clinical and molecular factors predictive of outcome with first-line sorafenib-based therapy in advanced renal carcinoma (RCC): An analysis of SWOG 0412 2007 ·Journal of Clinical Oncology ·Bryan Goldman, Primo N. Lara, Tomasz M. Beer, Philip C. Mack, Harry A. Drabkin, William Holland, E. David Crawford, Christopher W. Ryan	2
16	Spontaneous Immortalization of Human Epidermal Cells with Naturally Elevated Telomerase 2006 ·Journal of Investigative Dermatology ·(unknown), Lei Zhou, Qin Qin, Yann Barrandon, Karen Easley, (unknown), Marjorie A. Phillips, William Holland, Paul H. Gumerlock, David M. Rocke, Robert H. Rice	15
17	Preclinical evaluation of the dual specific Src/Abl kinase inhibitor AZD0530 in lung cancer 2006 ·Journal of Clinical Oncology ·Oliver Gautschi, Phillip R. Purnell, Christopher P. Evans, Joy C. Yang, William Holland, Richard J. Bold, S. Virudachalam, Primo N. Lara, David R. Gandara, Paul H. Gumerlock	5
18	Proeasome inhibition with bortezomib (PS-341) in combination with docetaxel (Doc) in prostate cancer (CaP) cells and xenografts 2005 ·Journal of Clinical Oncology ·(unknown), William Holland, (unknown), Tatsuo Kimura, Primo N. Lara, David R. Gandara, Paul H. Gumerlock	3
19	Differential in vivo activity of docetaxel plus PS-341 combination therapy in non-small cell lung carcinoma (NSCLC) xenografts 2004 ·Journal of Clinical Oncology ·Paul H. Gumerlock, Tatsuo Kimura, William Holland, (unknown), Primo N. Lara, David R. Gandara	7
20	Measurement of radical production as a result of cavitation in medical ultrasound fields 1997 ·Ultrasonics Sonochemistry ·Gareth J. Price, Francis Duck, (unknown), William Holland, (unknown)	39

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact